Life sciences sector financing experienced a slowdown in the first half of 2025, with total venture funding decreasing to $12.7 billion from $16.9 billion in 2024, as reported by BioCentury. Private investments in life science tools and diagnostics firms rose by 6 percent despite economic uncertainties surrounding tariffs and federal spending cuts, totaling $1.47 billion over 56 deals in H1 2025. However, average deal sizes declined 17 percent. Key financings included Colossal Biosciences' $200 million Series C and Caris Life Sciences' $168 million raise. Additionally, Austin reports suggest biopharma overall is facing funding difficulties and slowed early-stage funding activity.